These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 32161311)
21. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Sufan RI; Jewett MA; Ohh M Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922 [TBL] [Abstract][Full Text] [Related]
22. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Nyhan MJ; O'Sullivan GC; McKenna SL Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984 [TBL] [Abstract][Full Text] [Related]
23. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals. Wu TK; Wei CW; Pan YR; Hsu RJ; Wu CY; Yu YL Sci Rep; 2019 Mar; 9(1):3207. PubMed ID: 30824757 [TBL] [Abstract][Full Text] [Related]
24. Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma. Chen K; Zeng J; Sun Y; Ouyang W; Yu G; Zhou H; Zhang Y; Yao W; Xiao W; Hu J; Xing J; Xiao K; Wu L; Chen Z; Ye Z; Xu H Cancer Commun (Lond); 2021 Apr; 41(4):316-332. PubMed ID: 33591636 [TBL] [Abstract][Full Text] [Related]
25. Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. Liu X; Simon JM; Xie H; Hu L; Wang J; Zurlo G; Fan C; Ptacek TS; Herring L; Tan X; Li M; Baldwin AS; Kim WY; Wu T; Kirschner MW; Gong K; Zhang Q Mol Cell; 2020 Mar; 77(6):1294-1306.e5. PubMed ID: 32023483 [TBL] [Abstract][Full Text] [Related]
29. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960 [TBL] [Abstract][Full Text] [Related]
30. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364 [TBL] [Abstract][Full Text] [Related]
31. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672 [TBL] [Abstract][Full Text] [Related]
32. Kindlin‑2 promotes clear cell renal cell carcinoma progression through the Wnt signaling pathway. Li M; Pei X; Wang G; Zhan J; Du J; Jiang H; Tang Y; Zhang H; He H Oncol Rep; 2017 Sep; 38(3):1551-1560. PubMed ID: 28677779 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. An J; Rettig MB Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702 [TBL] [Abstract][Full Text] [Related]
35. Yao X; Tan J; Lim KJ; Koh J; Ooi WF; Li Z; Huang D; Xing M; Chan YS; Qu JZ; Tay ST; Wijaya G; Lam YN; Hong JH; Lee-Lim AP; Guan P; Ng MSW; He CZ; Lin JS; Nandi T; Qamra A; Xu C; Myint SS; Davies JOJ; Goh JY; Loh G; Tan BC; Rozen SG; Yu Q; Tan IBH; Cheng CWS; Li S; Chang KTE; Tan PH; Silver DL; Lezhava A; Steger G; Hughes JR; Teh BT; Tan P Cancer Discov; 2017 Nov; 7(11):1284-1305. PubMed ID: 28893800 [TBL] [Abstract][Full Text] [Related]
36. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860 [TBL] [Abstract][Full Text] [Related]
37. High expression of the secreted protein dickkopf homolog 4: roles in invasion and metastasis of renal cell carcinoma and its association with Von Hippel-Lindau gene. Zhai W; Hu GH; Zheng JH; Peng B; Liu M; Huang JH; Wang GC; Yao XD; Xu YF Int J Mol Med; 2014 May; 33(5):1319-26. PubMed ID: 24573574 [TBL] [Abstract][Full Text] [Related]
38. Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC). Martin B; Chesnel F; Delcros JG; Jouan F; Couturier A; Dugay F; Le Goff X; Patard JJ; Fergelot P; Vigneau C; Rioux-Leclerq N; Arlot-Bonnemains Y PLoS One; 2013; 8(6):e67071. PubMed ID: 23785518 [TBL] [Abstract][Full Text] [Related]
39. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation. Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971 [TBL] [Abstract][Full Text] [Related]
40. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma. Zhang ZY; Zhang SL; Chen HL; Mao YQ; Li ZM; Kong CY; Han B; Zhang J; Chen YH; Xue W; Zhai W; Wang LS Cell Prolif; 2020 Jul; 53(7):e12853. PubMed ID: 32537867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]